90 Participants NeededMy employer runs this trial

EDG-15400 for Heart Failure

(EQUINOX Trial)

Recruiting at 24 trial locations
SD
Overseen ByStudy Director: Medical Director, Edgewise Therapeutics, Inc.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Edgewise Therapeutics, Inc.
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with heart failure with preserved ejection fraction (HFpEF). Participants should meet specific medical criteria related to their heart condition. People with other major health issues or who don't fit the study's requirements cannot join.

Inclusion Criteria

I am taking a GLP-1 agonist and do not plan to change my dose during the study.
LVEF ≥ 50%
Body weight ≥ 45 kg, BMI < 40
See 4 more

Exclusion Criteria

I have moderate or severe interstitial lung disease or need oxygen for my lung condition.
I have severe COPD or need long-term oxygen therapy for my COPD.
I have been diagnosed with hypertrophic cardiomyopathy.
See 3 more

What Are the Treatments Tested in This Trial?

Trial Overview

The study is testing two different doses of a new drug called EDG-15400 compared to a placebo (inactive pill) in people with HFpEF, to see how safe and tolerable the drug is. Participants are randomly assigned to one of the groups.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Placebo Group

Group I: EDG-15400 50 mgExperimental Treatment1 Intervention
Group II: EDG-15400 25 mgExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Edgewise Therapeutics, Inc.

Lead Sponsor

Trials
13
Recruited
1,000+